Patterns of Retreatment by Radiotherapy

Bartoň, Michael; Allen, S.; Delaney, Geoff P.; Hudson, H. Malcolm; Zhang, Hao; Allison, Roger; Linden, Y.M. van der

doi:10.1016/j.clon.2014.03.008

Cited by 25 publications

(7 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, in the countries where retreatments were included, the courses were adjusted by a factor of 0.80 in order to compensate for the increment of 25% typically applied for retreatments [5]. This approach has been taken due to the lack of consistent data across European countries on the retreatments carried out; until now only local analyses have been published [10][11][12], mostly from outside Europe. Thus, the option here has been to focus on data for new cancer cases.…”

Section: Methodsmentioning

confidence: 99%

The optimal utilization proportion of external beam radiotherapy in European countries: An ESTRO-HERO analysis

Borràs

Lievens

Dunscombe

et al. 2015

Radiotherapy and Oncology

142

View full text Add to dashboard Cite

a b s t r a c tBackground and purpose: The absolute number of new cancer patients that will require at least one course of radiotherapy in each country of Europe was estimated. Material and methods: The incidence and relative frequency of cancer types from the year 2012 European Cancer Observatory estimates were used in combination with the population-based stage at diagnosis from five cancer registries. These data were applied to the decision trees of the evidence-based indications to calculate the Optimal Utilization Proportion (OUP) by tumour site. Results: In the minimum scenario, the OUP ranged from 47.0% in the Russian Federation to 53.2% in Belgium with no clear geographical pattern of the variability among countries. The impact of stage at diagnosis on the OUP by country was rather limited. Within the 24 countries where data on actual use of radiotherapy were available, a gap between optimal and actual use has been observed in most of the countries. Conclusions: The actual utilization of radiotherapy is significantly lower than the optimal use predicted from the evidence based estimates in the literature. This discrepancy poses a major challenge for policy makers when planning the resources at the national level to improve the provision in European countries.Ó 2015 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology xxx (2015) xxx-xxxThe estimated number of new cancer patients that require radiotherapy is a key parameter for planning the resources needed in a specific country in the framework of a cancer control programme. Most commonly, this calculation has been carried out using a specific proportion, typically the 'gold standard' of 50%, of the incident cases that would require radiotherapy at least http://dx

show abstract

Section: Methodsmentioning

confidence: 99%

The optimal utilization proportion of external beam radiotherapy in European countries: An ESTRO-HERO analysis

Borràs

Lievens

Dunscombe

et al. 2015

Radiotherapy and Oncology

142

View full text Add to dashboard Cite

show abstract

“…About 90% of all head and neck cancers are squamous cell carcinomas (HNSCC) [4]. Apart of surgery the main treatment protocol for HNSCC is radiotherapy (RT) combined with chemotherapy [5].…”

Section: Introductionmentioning

confidence: 99%

Radiotherapy-Induced Changes in the Systemic Immune and Inflammation Parameters of Head and Neck Cancer Patients

Balázs

Kis

Badie

et al. 2019

Cancers

View full text Add to dashboard Cite

Though radiotherapy is a local therapy, it has systemic effects mainly influencing immune and inflammation processes. This has important consequences in the long-term prognosis and therapy individualization. Our objective was to investigate immune and inflammation-related changes in the peripheral blood of head and neck cancer patients treated with radiotherapy. Peripheral blood cells, plasma and blood cell-derived RNA were isolated from 23 patients before and at two time points after radiotherapy and cellular immune parameters, plasma protein changes and gene expression alterations were studied. Increased regulatory T cells and increased CTLA4 and PD-1 expression on CD4 cells indicated an immune suppression induced by the malignant condition, which was accentuated by radiotherapy. Circulating dendritic cells were strongly elevated before treatment and were not affected by radiotherapy. Decreased endoglin levels in the plasma of patients before treatment were further decreased by radiotherapy. Expression of the FXDR, SESN1, GADD45, DDB2 and MDM2 radiation-response genes were altered in the peripheral blood cells of patients after radiotherapy. All changes were long-lasting, detectable one month after radiotherapy. In conclusion we demonstrated radiotherapy-induced changes in systemic immune parameters of head and neck cancer patients and proposed markers suitable for patient stratification worth investigating in larger patient cohorts.

show abstract

“…Finally, our model only considered the proportion of patients requiring SABR as initial therapy, without accounting for those requiring re-treatments. Barton et al (2014) reported 16% of lung cancer patients requiring re-treatments [76] , although this rate included all stages and types/intents of radiotherapy and may be different for SABR treatments. Thorax re-irradiation with SABR has shown to be feasible in retrospective studies, in particularl, for salvaging residual, recurrent or new primary NSCLC in or adjacent to a previous high-dose radiation field [77] , [78] , [79] , [80] , [81] .…”

Section: Discussionmentioning

confidence: 99%

Optimal and actual rates of Stereotactic Ablative Body Radiotherapy (SABR) utilisation for primary lung cancer in Australia

Ghandourh

Holloway

Batumalai

et al. 2022

Clinical and Translational Radiation Oncology

View full text Add to dashboard Cite

Patterns of Retreatment by Radiotherapy

Cited by 25 publications

References 15 publications

The optimal utilization proportion of external beam radiotherapy in European countries: An ESTRO-HERO analysis

The optimal utilization proportion of external beam radiotherapy in European countries: An ESTRO-HERO analysis

Radiotherapy-Induced Changes in the Systemic Immune and Inflammation Parameters of Head and Neck Cancer Patients

Optimal and actual rates of Stereotactic Ablative Body Radiotherapy (SABR) utilisation for primary lung cancer in Australia

Contact Info

Product

Resources

About